Inflammatory Bowel Disease Treatment Market Growth Forecast: Exploring Trends and Opportunities for the Next Decade
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What Growth Opportunities are Expected to Drive the Inflammatory Bowel Disease Treatment Market’s CAGR Through 2034?
In the past few years, the market size for inflammatory bowel disease treatment has seen a robust growth. It is set to expand from $25.26 billion in 2024 to approximately $27.45 billion in 2025, at a Compound Annual Growth Rate (CAGR) of 8.6%. This growth during the historical period can be ascribed to factors like increased occurrence of inflammatory bowel disease, the rising demand for biologics and immunomodulators, advancements in the treatment alternatives, an increasing elderly population, and heightened awareness about the disease.
The market for treatment of inflammatory bowel disease is projected to experience swift expansion in the coming years, with its value expected to reach $40.27 billion in 2029, signifying a compound annual growth rate (CAGR) of 10.1%. The anticipated growth over the forecast period can be linked to incremental investment in research and development of new treatment techniques, burgeoning demand for biosimilars, an increase in instances of inflammatory bowel diseases in developing markets, a surge in demand for customized medication, and integration of precision medicine in IBD treatment protocols. Major trends to look out for within this period include a rise in the number of product launches and approvals, the application of personalized dosing and treatment strategies in managing IBD, the utilization of telemedicine for distant monitoring of IBD patients, the exploration of microbiome-rooted therapies for IBD, and the adoption of value-based care schemas in IBD treatment.
What Industry-Specific Factors Are Fueling the Growth of the inflammatory bowel disease treatment Market?
The escalating incidences of Crohn’s disease and ulcerative colitis are notably fueling the development of the inflammatory bowel disease treatment marketplace. Crohn’s disease and ulcerative colitis, known as types of inflammatory bowel diseases (IBD), trigger inflammation and the formation of ulcers (sores) in the digestive systems. The mounting occurrences of these diseases are presumed to elevate the demand for inflammatory bowel disease therapies, which are broadly practiced to lessen bowel inflammation and mitigate and avert medical complications. As indicated by research published in the United States National Library of Medicine in March 2022, an American medical library, roughly 1.6 million Americans are currently living with inflammatory bowel disease (Crohn’s disease or ulcerative colitis), with about 70,000 fresh instances of IBD identified annually in the USA. As such, the growing incidences of Crohn’s disease and ulcerative colitis are anticipated to propel the growth of the inflammatory bowel disease treatment marketplace.
Request Your Free Inflammatory Bowel Disease Treatment Market Report Sample Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=6704&type=smp
Who Are the Major Companies Shaping the Competitive Landscape of the Inflammatory Bowel Disease Treatment Market?
Major companies operating in the inflammatory bowel disease treatment market include:
• AbbVie Inc._x000D_
• Biogen Inc._x000D_
• Johnson & Johnson_x000D_
• Amgen Inc._x000D_
• Advanced Gastroenterology and Surgery Associates P. A._x000D_
What Are the Key Emerging Trends in the Inflammatory Bowel Disease Treatment Market for the Next Decade?
In the inflammatory bowel disease treatment market, technological progression is becoming an increasingly prevalent trend. Major players in the market are turning their focus to AI-powered registries to maintain a competitive edge. For example, in May 2024, Verantos, a firm based in California specializing in real-world evidence (RWE), introduced its Inflammatory Bowel Disease Pragmatic Registry, utilising sophisticated artificial intelligence to create high-quality real-world evidence for Crohn’s disease and ulcerative colitis. The registry aims to promote the creation of effective treatments by presenting a comprehensive dataset that includes over 3 billion data points on patient care. By utilising both structured and unstructured data from electronic health records, it lets biopharma researchers obtain precise assessments of disease severity, treatment efficacy and clinical outcomes.
Pre-order Your Report for Quick and Easy Delivery!
What Are the Strategic Segments Comprising the Inflammatory Bowel Disease Treatment Market and Their Growth Contributions?
The inflammatory bowel disease treatment market covered in this report is segmented –
1) By Drug Class: Aminosalicylates, Corticosteroids, TNF inhibitors, IL inhibitors, Anti-integrin, JAK inhibitors, Other Drug Classes
2) By Type: Crohn’s Disease, Ulcerative Colitis
3) By Route Of Administration: Oral, Injectable
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Aminosalicylates: Mesalamine, Sulfasalazine, Balsalazide
2) By Corticosteroids: Prednisone, Budesonide, Hydrocortisone
3) By TNF Inhibitors: Infliximab, Adalimumab, Certolizumab pegol
4) By IL Inhibitors: Ustekinumab, Guselkumab
5) By Anti-Integrin: Vedolizumab, Natalizumab
6) By JAK Inhibitors: Tofacitinib, Filgotinib
7) By Other Drug Classes: Antibiotics, Immunosuppressants, Other Novel Therapies
Which Regions Are Making a Mark in the Inflammatory Bowel Disease Treatment Market Growth?
North America was the largest region in the inflammatory bowel disease treatment market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inflammatory bowel disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
What Are the Defining Aspects of the Inflammatory Bowel Disease Treatment Market Landscape?
Inflammatory bowel disease treatment refers to anti-inflammatory medications that are commonly used to treat mild to moderate ulcerative colitis. Aminosalicylates such as mesalamine (Delzicol, Rowasa, and other brands), balsalazide (Colazal), and olsalazine are anti-inflammatories (Dipentum).
Browse Through More Similar Reports By The Business Research Company:
Microbiome Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/microbiomes-global-market-report
Digestive Enzymes Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/digestive-enzyme-global-market-report
C-Reactive Protein Testing Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/c-reactive-protein-testing-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
